Document is current
Any future updates will be listed below
-
Authors
Klein, Jon http://orcid.org/0000-0002-3552-7684
Wood, Jamie
Jaycox, Jillian R.
Dhodapkar, Rahul M. http://orcid.org/0000-0002-2014-7515
Lu, Peiwen http://orcid.org/0000-0001-6118-872X
Gehlhausen, Jeff R.
Tabachnikova, Alexandra
Greene, Kerrie
Tabacof, Laura
Malik, Amyn A.
Silva Monteiro, Valter http://orcid.org/0000-0003-1785-6713
Silva, Julio http://orcid.org/0000-0001-8212-7440
Kamath, Kathy
Zhang, Minlu http://orcid.org/0000-0003-2347-0569
Dhal, Abhilash
Ott, Isabel M.
Valle, Gabrielee
Peña-Hernández, Mario
Mao, Tianyang http://orcid.org/0000-0001-9251-8592
Bhattacharjee, Bornali http://orcid.org/0000-0002-0801-1543
Takahashi, Takehiro http://orcid.org/0000-0002-1061-356X
Lucas, Carolina http://orcid.org/0000-0003-4590-2756
Song, Eric http://orcid.org/0000-0001-5448-5865
McCarthy, Dayna
Breyman, Erica
Tosto-Mancuso, Jenna
Dai, Yile http://orcid.org/0000-0002-7761-3361
Perotti, Emily
Akduman, Koray
Tzeng, Tiffany J.
Xu, Lan
Geraghty, Anna C.
Monje, Michelle http://orcid.org/0000-0002-3547-237X
Yildirim, Inci http://orcid.org/0000-0002-8631-0020
Shon, John
Medzhitov, Ruslan http://orcid.org/0000-0002-7021-2012
Lutchmansingh, Denyse
Possick, Jennifer D.
Kaminski, Naftali http://orcid.org/0000-0001-5917-4601
Omer, Saad B. http://orcid.org/0000-0002-5383-3474
Krumholz, Harlan M. http://orcid.org/0000-0003-2046-127X
Guan, Leying
Dela Cruz, Charles S. http://orcid.org/0000-0002-5258-1797
van Dijk, David http://orcid.org/0000-0003-3911-9925
Ring, Aaron M. http://orcid.org/0000-0003-3699-2446
Putrino, David http://orcid.org/0000-0002-2232-3324
Iwasaki, Akiko http://orcid.org/0000-0002-7824-9856
- License Information
-
More Information
Article History
Received: 8 August 2022
Accepted: 18 September 2023
First Online: 25 September 2023
Competing interests
: In the past three years, H.M.K. received expenses and/or personal fees from UnitedHealth, Element Science, Eyedentifeye and F-Prime; he is a co-founder of Refactor Health and HugoHealth; and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from the Food and Drug Administration, Johnson & Johnson, Google and Pfizer. N.K. is a scientific founder at Thyron; served as a consultant to Boehringer Ingelheim, Pliant, Astra Zeneca, RohBar, Veracyte, Galapagos, Fibrogen and Thyron over the past 3 years; reports equity in Pliant and Thyron; and acknowledges grants from Veracyte, Boehringer Ingelheim and BMS. A.I. co-founded and consults for RIGImmune, Xanadu Bio and PanV; consults for Paratus Sciences and InvisiShield Technologies; and is a member of the Board of Directors of Roche Holding. A.M.R. and Y.D. are listed as inventors on a patent describing the REAP technology. A.M.R. is the founder and director of Seranova Bio. A.M.R. and Y.D. hold equity in Seranova Bio. The other authors declare no competing interests.
